EUCTR2015‐005279‐25‐DE.

Methods	Randomised, placebo‐controlled, parallel‐group, double‐blind Date of study: September 2016 (starting date) Location: Germany
Participants	Total sample size: 36 Inclusion criteria Signed and dated informed consent Aged between 18 years and 65 Men or women of non‐childbearing potential Clinical diagnosis of psoriasis vulgaris with or without psoriatic arthritis Have moderate‐to‐severe psoriasis vulgaris Candidates of systemic anti‐psoriatic treatment and/or phototherapy Exclusion criteria Patients with therapy‐resistant psoriasis Previously exposed to apremilast Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris Systemic treatment with all other therapies (other than biologics) with a possible effect on psoriasis vulgaris
Interventions	Intervention 1: LEO 32731 30 mg twice a day for 16 weeks Intervention 2: placebo
Outcomes	Primary outcome Psoriasis Area and Severity Index (PASI) at week 16 Secondary outcome Proportion of participants with Physician's Global Assessment of Disease Severity (PGA) treatment success, defined as clear or almost clear at week 16 Itch evaluated by itch Numerical Rating Scale (NRS) at week 16
Notes	Study completion date on ClinicalTrials.gov July 2017 NCT02888236